# EDGAR Filing Document

**Accession Number:** 0001844645
**File Stem:** 0001012975-25-000494
**Filing Date:** 2025-8
**Character Count:** 4830
**Document Hash:** 936bb9d120f212e6e016fb7ebd3fd721
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001012975-25-000494.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001012975-25-000494

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pivotal bioVenture Partners Investment Advisor LLC
- **CENTRAL INDEX KEY:** 0001844645

**ORGANIZATION NAME:**
- **EIN:** 814749159
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-20630
- **FILM NUMBER:** 251280810

**BUSINESS ADDRESS:**
- **STREET 1:** 501 2ND ST, SUITE 200
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107
- **BUSINESS PHONE:** 415-948-7474

**MAIL ADDRESS:**
- **STREET 1:** 501 2ND ST, SUITE 200
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001844645

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Pivotal bioVenture Partners Investment Advisor LLC

**Address:** 501 2ND ST, SUITE 200, SAN FRANCISCO, CA 94107

**Telephone number:** 415-948-7474

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-20630

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 1

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER               | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                           | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   | SHARES VOTED FOR OR AGAINST MANAGEMENT   | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|:---|:---|:---|
| ARCUTIS BIOTHERAPEUTICS INC  | 03969K108 | 06/12/2025     | To approve, on a non-binding basis, the compensation of the Company's named executive officers.                                            | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| OCULIS HOLDING AG            | H5870P102 | 06/12/2025     | To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers                                    | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| RECURSION PHARMACEUTICALS IN | 75629V104 | 06/18/2025     | To approve the compensation of our Named Executive Officers                                                                                | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| TREVI THERAPEUTICS INC       | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the compensation paid to our named executive officers                                                   | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| TREVI THERAPEUTICS INC       | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| VAXCYTE INC                  | 92243G108 | 06/12/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement         | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |

## N-PX: Signature Block

**Reporting Person:** Pivotal bioVenture Partners Investment Advisor LLC

**By (Signature):** Robert Hopfner

**By (Printed Signature):** Robert Hopfner

**By (Title):** Managing Partner

**Date:** 08/29/2025